Novo Nordisk reported results for the first half of 2025 on Wednesday, days after issuing a profit warning that triggered a 23% single-day share price plunge — the steepest in its history.
The results were broadly in line with expectations. In the first six months of 2025, Novo Nordisk's sales increased by 16% in Danish kroner and by 18% at constant exchange rates (CER) to DKK 154.9bn (€20.77bn).
